Andrew N Stephens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8339937/publications.pdf

Version: 2024-02-01

52 papers

1,757 citations

257101 24 h-index 288905 40 g-index

54 all docs 54 docs citations

54 times ranked 3128 citing authors

#	Article	IF	CITATIONS
1	2D-DiGE Analysis of the Human Endometrial Secretome Reveals Differences between Receptive and Nonreceptive States in Fertile and Infertile Women. Journal of Proteome Research, 2010, 9, 6256-6264.	1.8	126
2	Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Medicine, 2015, 7, 87.	3.6	126
3	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
4	Proteomic Characterization of Midproliferative and Midsecretory Human Endometrium. Journal of Proteome Research, 2009, 8, 2032-2044.	1.8	96
5	Proteomics of the human endometrium and uterine fluid: a pathway to biomarker discovery. Fertility and Sterility, 2013, 99, 1086-1092.	0.5	83
6	Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. Current Medicinal Chemistry, 2018, 25, 4785-4806.	1.2	80
7	Post-Translational Modifications and Protein-Specific Isoforms in Endometriosis Revealed by 2D DIGE. Journal of Proteome Research, 2010, 9, 2438-2449.	1.8	76
8	Proteomic Changes in Rat Spermatogenesis in Response to In Vivo Androgen Manipulation; Impact on Meiotic Cells. PLoS ONE, 2012, 7, e41718.	1.1	61
9	Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Frontiers in Immunology, 2017, 8, 1482.	2.2	53
10	Identification of novel dipeptidyl peptidase 9 substrates by twoâ€dimensional differential inâ€gel electrophoresis. FEBS Journal, 2015, 282, 3737-3757.	2.2	51
11	Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 552-560.	0.6	49
12	Therapeutic Targeting of Collective Invasion in Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 1466.	1.8	47
13	The emerging role of CXC chemokines in epithelial ovarian cancer. Reproduction, 2012, 144, 303-317.	1.1	42
14	Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells. Cancers, 2019, 11, 1228.	1.7	39
15	Evidence for the antagonistic form of CXCâ€motif chemokine CXCL10 in serous epithelial ovarian tumours. International Journal of Cancer, 2014, 134, 530-541.	2.3	38
16	Discovery and Validation of Novel Protein Biomarkers in Ovarian Cancer Patient Urine. Proteomics - Clinical Applications, 2018, 12, e1700135.	0.8	37
17	Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. Scientific Reports, 2020, 10, 2213.	1.6	37
18	The Molecular Neighborhood of Subunit 8 of Yeast Mitochondrial F1F0-ATP Synthase Probed by Cysteine Scanning Mutagenesis and Chemical Modification. Journal of Biological Chemistry, 2003, 278, 17867-17875.	1.6	36

#	Article	IF	Citations
19	Posttranslational Activation of Bone Morphogenetic Protein 2 Is Mediated by Proprotein Convertase 6 during Decidualization for Pregnancy Establishment. Endocrinology, 2010, 151, 3909-3917.	1.4	31
20	Proprotein Convertase 5/6 Is Critical for Embryo Implantation in Women: Regulating Receptivity by Cleaving EBP50, Modulating Ezrin Binding, and Membrane-Cytoskeletal Interactions. Endocrinology, 2011, 152, 5041-5052.	1.4	31
21	HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors. Journal of Cancer, 2013, 4, 152-164.	1.2	31
22	Depletion of High-Abundance Serum Proteins from Human Uterine Lavages Enhances Detection of Lower-Abundance Proteins. Journal of Proteome Research, 2009, 8, 1099-1103.	1.8	30
23	Proteomic Approach Identifies Alterations in Cytoskeletal Remodelling Proteins during Decidualization of Human Endometrial Stromal Cells. Journal of Proteome Research, 2010, 9, 5739-5747.	1.8	26
24	Proteomic Analysis of the Intestinal Adaptation Response Reveals Altered Expression of Fatty Acid Binding Proteins Following Massive Small Bowel Resection. Journal of Proteome Research, 2010, 9, 1437-1449.	1.8	23
25	Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 183-192.	1.1	23
26	Application of the wheat-germ cell-free translation system to produce high temperature requirement A3 (HtrA3) proteases. BioTechniques, 2012, 52, 23-28.	0.8	21
27	The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine. Journal of Proteome Research, 2013, 12, 4074-4088.	1.8	21
28	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	2.9	21
29	Topology and proximity relationships of yeast mitochondrial ATP synthase subunit 8 determined by unique introduced cysteine residues. FEBS Journal, 2000, 267, 6443-6451.	0.2	20
30	Proteomics and the search for biomarkers of female reproductive diseases. Reproduction, 2010, 140, 505-519.	1.1	20
31	Proteomic Identification of Caldesmon as a Physiological Substrate of Proprotein Convertase 6 in Human Uterine Decidual Cells Essential for Pregnancy Establishment. Journal of Proteome Research, 2009, 8, 4983-4992.	1.8	19
32	Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. Cancers, 2019, 11, 32.	1.7	16
33	DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers, 2021, 13, 487.	1.7	16
34	Mapping the testicular interstitial fluid proteome from normal rats. Proteomics, 2016, 16, 2391-2402.	1.3	14
35	New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators. Current Medicinal Chemistry, 2018, 25, 4758-4784.	1.2	14
36	An optimized procedure for the capture, fractionation and proteomic analysis of proteins using hydrogel nanoparticles. Proteomics, 2010, 10, 332-336.	1.3	13

3

#	Article	IF	CITATIONS
37	EPO-receptor is present in mouse C2C12 and human primary skeletal muscle cells but EPO does not influence myogenesis. Physiological Reports, 2014, 2, e00256.	0.7	13
38	Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 8110.	1.8	12
39	Each yeast mitochondrial F1F0-ATP synthase complex contains a single copy of subunit 8. Biochimica Et Biophysica Acta - Bioenergetics, 2003, 1607, 181-189.	0.5	11
40	Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression. Cancers, 2018, 10, 276.	1.7	11
41	Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget, 2016, 7, 46573-46578.	0.8	9
42	Combination of hydrogel nanoparticles and proteomics to reveal secreted proteins associated with decidualization of human uterine stromal cells. Proteome Science, 2011, 9, 50.	0.7	6
43	Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent <i>in vivo</i> activity through an ROS-dependent mechanism. Metallomics, 2021, 13, .	1.0	6
44	Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer. Diagnostics, 2021, 11, 1048.	1.3	5
45	Chemoresistance is mediated by ovarian cancer leader cells in vitro. Journal of Experimental and Clinical Cancer Research, 2021, 40, 276.	3.5	5
46	Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics, 2021, 11, 69.	1.3	5
47	Total PC Activity Is Increased in Uterine Lavage of Post-Menopausal Endometrial but Not Ovarian Cancer Patients. Journal of Cancer, 2016, 7, 1812-1814.	1.2	3
48	Proteomic Identification of Proprotein Convertase 6 Substrates in Human Endometrial Stromal Cells During Decidualization Biology of Reproduction, 2008, 78, 57-57.	1.2	3
49	Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy. Cancers, 2021, 13, 4201.	1.7	1
50	A Proteomic Protocol to Identify Physiological Substrates of Pro-protein Convertases. Methods in Molecular Biology, 2011, 768, 325-341.	0.4	1
51	Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option. , 0, , .		0
52	Proteomic Analysis of Endometrial Lavage Samples Provides New Insights into Proteins Important for Implantation Biology of Reproduction, 2008, 78, 142-143.	1.2	0